TSTatyana N. Sokolova

Tatyana N. Sokolova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatyana N. Sokolova has a total of 247 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of HLA Genotypes in the Age Variability at Onset of BRCA1-Associated Breast Cancer

    by Арина Андреевна Перевалова, Александр Сергеевич Мартьянов, Екатерина Шотовна Кулигина, Александр Андреевич Романько, Татьяна Николаевна Соколова, Татьяна Эдуардовна Янкевич, Дмитрий Юрьевич Трофимов, Евгений Наумович Имянитов

    Введение. Носительницы патогенных вариантов гена BRCA1 характеризуются значительной вариабельностью возраста манифестации рака молочной железы (РМЖ). HLA I и II классов играют ключевую роль в презентации опухолевых антигенов, однако существующие полногеномные исследования ассоциаций (GWAS) не позволяют оценить их вклад в модификацию пенетрантности из-за высокой полиморфности и структурной сложности этого региона генома, вследствие чего роль генотипов HLA в возраст-зависимой реализации риска BRCA1-ассоциированного РМЖ остается неизученной. Цель. Оценить связь генотипов локусов HLA I и II классов, а также гомозиготности HLA с возрастом манифестации РМЖ у носительниц мутаций BRCA1. Материалы и методы. В исследование включено 323 носительницы патогенных аллелей BRCA1 с верифицированным РМЖ из России и Польши, разделенные на группы с ранним (≤ 39 лет, n = 215) и поздним (≥ 57 лет, n = 108) дебютом заболевания. HLA-типирование локусов А, В, С, DPB1, DQB1, DRB1/3/4/5 выполняли методом высокопроизводительного секвенирования (NGS). Частоты аллелей и долю гомозиготных генотипов сравнивали с использованием критерия χ² и точного критерия Фишера; рассчитывали отношение рисков (ОР). Результаты. Аллель HLA-DQB1*06:03P статистически значимо чаще встречался в группе с поздним началом РМЖ по сравнению с группой раннего дебюта (13,8 против 5,1 %; ОР = 2,91 (95 % ДИ 1,62–5,22); p = 0,0001). Аллель HLA-C*03:04P ассоциирован с повышенным риском ранней манифестации (7,7 против 3,2 %; p = 0,027). Обнаружена статистически значимая связь гомозиготности по локусу HLA-A с развитием РМЖ в молодом возрасте (14,4 против 6,5 %; ОР = 2,4 (95 % ДИ: 1,03–5,72); p = 0,037). Для остальных локусов HLA класса I прослеживалась аналогичная тенденция к преобладанию гомозигот у пациенток с ранним дебютом. Выводы. Генотип HLA может модифицировать возраст-зависимую пенетрантность патогенных мутаций BRCA1. Наличие аллеля HLA-DQB1*06:03P ассоциировано с отсроченным развитием РМЖ; гомозиготность по локусам HLA класса I способствует более ранней реализации онкологического риска.

  • Open Access

    Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients

    by Tatyana N. Sokolova, Grigory A. Yanus, Svetlana N. Aleksakhina, Yana V. Belysheva, Aleksandra P. Chernyakova, Yulia S. Zharnakova, Alisa S. Nikitina, Tatyana M. Stebneva, Aleksandr S. Martianov, Alla Yu. Goryainova, et al.

    Background: Several targeted drugs have been recently approved for the treatment of PIK3CA-mutated hormone receptor-positive (HR+)/HER2-negative (HER2−) breast cancer (BC). This study aimed at a comprehensive evaluation of the spectrum of PIK3CA alterations in Russian BC patients. Methods: The tumor material from 1872 patients with ER+/HER2− BC was tested by a combination of PCR-based methods. Results: Mutations were detected in 693/1872 (37%) cases, including 46 BC with two PIK3CA lesions. The three most common substitutions (E542K, E545K, and H1047R) were identified in 542/693 (78%) PIK3CA-mutated cases, while as many as 5.5–12% of identified mutations were not potentially detectable by common commercial kits. The study included patients of Slavic and non-Slavic ethnicities residing in regions with different climate conditions, however, these factors did not influence the distribution of PIK3CA mutations. The presence of PIK3CA variants was associated with older patient age at diagnosis (p = 0.0002), smaller tumor size (p = 0.005), lower grade (p = 0.005), Ki67 <20% (p = 0.0001) and progesterone receptor-positive status (p = 0.002) at the initial disease diagnosis, and fewer distant metastases at the time of the detection of BC spread (p = 0.0001). In a subgroup of 413 BC patients who received adjuvant tamoxifen or aromatase inhibitors, PIK3CA mutations were not associated with resistance to either type of treatment. Conclusions: The results of this study highlight the need to extend the PIK3CA testing beyond the hotspot regions of this gene. Although PIK3CA alterations contribute to the pathogenesis of HR+/HER2− BC and represent a target for several novel drugs, they are not intrinsically associated with unfavorable clinical characteristics of this subtype of cancer disease.


  • HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles

    by Ekaterina S. Kuligina, Alexandr A. Romanko, Tatjana Jankevic, Aleksandr S. Martianov, Alexandr O. Ivantsov, Tatyana N. Sokolova, Dmitry Trofimov, Aniruddh Kashyap, Cezary Cybulski, Jan Lubiński, et al.

    Purpose Female carriers of germline BRCA1 mutations almost invariably develop breast cancer (BC); however, the age at onset is a subject of variation. We hypothesized that the age-related penetrance of BRCA1 mutations may depend on inherited variability in the host immune system. Methods Next-generation sequencing was utilized for genotyping of HLA class I/II genes (HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQB1, and HLA-DRB1/3/4/5) in patients with BRCA1-associated BC with early (< / = 38 years, n = 215) and late (> / = 58 years, n = 108) age at onset. Results HLA-DQB1*06:03P prevalence was higher in the late-onset group due to the excess of allele carriers [25/108 (23.1%) vs. 22/215 (10.2%); OR 2.96, p < 0.001]. For all HLA-I loci, there was a trend toward an increase in the number of homozygotes in the early-onset group. This trend reached statistical significance for the HLA-A [14.4% vs. 6.5%, p = 0.037; OR 2.4, p = 0.042]. The frequencies of HLA-DPB1, HLA-DQB1, and HLA-DRB1/3/4/5 homozygous genotypes did not differ between young-onset and late-onset patients. The maximum degree of homozygosity detected in this study was 6 out of 7 HLA class I/II loci; all six carriers of these genotypes were diagnosed with BC at the age < / = 38 years [OR 6.97, p = 0.187]. Conclusion HLA polymorphism may play a role in modifying the penetrance of BRCA1 pathogenic variants. Certain HLA alleles or HLA homozygosity may modify the risk of BC in BRCA1 carriers.


  • Open Access

    Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer

    by Alexey V. Emshanov, Denis V. Nesterov, Tatyana N. Sokolova, Priscilla S. Amankwah, Evgeny N. Imyanitov

    Early clinical trials aimed to halt cancer progression by inhibiting the growth of new blood vessels in tumors through single-agent targeted therapy with bevacizumab. These trials largely proved unsuccessful. However, bevacizumab turned out to be efficient when administered in combination with other anticancer drugs. The efficacy of this approach is explained by the ability of bevacizumab to eliminate immature blood vessels thus normalizing intratumoral blood flow and improving the delivery of cytotoxic or targeted agents. This report describes four cases of heavily pretreated patients with metastatic HER2-positive breast cancer, who had no meaningful treatment options left, and who received single-agent bevacizumab as an empirical last-resort therapy. Three of these patients had severe complaints, and they demonstrated striking symptomatic relief within the first day of this treatment. In addition to the observed “Lazarus response”, which was likely attributed to the bevacizumab-driven resolution of edema, some evidence of a direct antitumor effect was observed. These data may call for the reconsideration of bevacizumab monotherapy in patients with HER2-associated breast cancer, and perhaps in some other categories of cancer patients.


  • Open Access

    Search for Novel Hereditary Ovarian Cancer Susceptibility Genes through Whole Exome Sequencing of Responders to Platinum-Based Therapy

    by Анна Соколенко, Роберт Бройде, Валерия Ни, Татьяна Соколова, Татьяна Городнова, Елена Савоневич, Римма Мулкиджан, Екатерина Кулигина, Евгений Имянитов

  • Open Access

    Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas

    by Vladislav I. Tiurin, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina, Aleksandr A. Romanko, Aleksandra A. Anuskina, Rimma S. Mulkidjan, Evgeniya S. Saitova, Elena A. Krivosheyeva, Elena D. Kharitonova, Mikhail P. Shevyakov, et al.

    RET-kinase-activating gene rearrangements occur in approximately 1–2% of non-small-cell lung carcinomas (NSCLCs). Their reliable detection requires next-generation sequencing (NGS), while conventional methods, such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) or variant-specific PCR, have significant limitations. We developed an assay that compares the level of RNA transcripts corresponding to 5′- and 3′-end portions of the RET gene; this test relies on the fact that RET translocations result in the upregulation of the kinase domain of the gene and, therefore, the 5′/3′-end expression imbalance. The present study included 16,106 consecutive NSCLC patients, 14,449 (89.7%) of whom passed cDNA quality control. The 5′/3′-end unbalanced RET expression was observed in 184 (1.3%) tumors, 169 of which had a sufficient amount of material for the identification of translocation variants. Variant-specific PCR revealed RET rearrangements in 155/169 (91.7%) tumors. RNA quality was sufficient for RNA-based NGS in 10 cases, 8 of which carried exceptionally rare or novel (HOOK1::RET and ZC3H7A::RET) RET translocations. We also applied variant-specific PCR for eight common RET rearrangements in 4680 tumors, which emerged negative upon the 5′/3′-end unbalanced expression test; 33 (0.7%) of these NSCLCs showed RET fusion. While the combination of the analysis of 5′/3′-end RET expression imbalance and variant-specific PCR allowed identification of RET translocations in approximately 2% of consecutive NSCLCs, this estimate approached 120/2361 (5.1%) in EGFR/KRAS/ALK/ROS1/BRAF/MET-negative carcinomas. RET-rearranged tumors obtained from females, but not males, had a decreased level of expression of thymidylate synthase (p < 0.00001), which is a known predictive marker of the efficacy of pemetrexed. The results of our study provide a viable alternative for RET testing in facilities that do not have access to NGS due to cost or technical limitations.


  • Open Access

    Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

    by Tatyana N. Sokolova, Tatyana I. Solov'EVa, Svetlana N. Aleksakhina, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Yana S. Chapko, Anna A. Shchukina, et al.

    Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of which harbors PIK3CA mutations that affect the catalytic subunit of the PI3K protein. PIK3CA alterations are actionable, as such neoplasms can be treated with a combination of fulvestrant and the PI3K inhibitor alpelisib. As PIK3CA mutations have an extremely versatile effect on the characteristics of a tumor cell, numerous associations of PIK3CA mutations and various clinico-pathological characteristics of BC can be traced. Aim. Our aim was to clarify the information on the frequency and spectrum of PIK3CA mutations in Russian patients with HR+/HER2- advanced BC, and to study the association of PIK3CA mutations with clinical and pathological parameters of BC. Materials and methods. Tissue samples from 694 patients with HR+/HER2- advanced BC (mixed population of primary metastatic and relapsed tumors) who received any line of anti-cancer treatment in Dec 2020 to June 2021 in Russian Federation were analyzed by high-resolution melting, allele-specific PCR, digital droplet PCR and Sanger sequencing (exons 7,9, and 20 of the PIK3CA gene). Mutation rates in different BC subgroups were compared using the Fishers exact test. The age at diagnosis in patients with different PIK3CA status was compared using the MannWhitney U-test. The relationship between the PIK3CA status and the degree of tumor differentiation was compared using the CochraneArmitage test for trends. Luminal A and B BC expression subtypes were distinguished with surrogate IHC markers according to St.-Gallen recommendations (2013). Results. Mutations were identified in 220/694 (32%) BC patients. The three most frequent missense substitutions in the PIK3CA gene (p.E542K, p.E545K, and p.H1047R) accounted for 190/220 (86%) mutations. Associations of PIK3CA mutations with luminal A subtype of BC, low proliferation index, small size of the primary tumor, and absence of signs of hereditary cancer were revealed. Associations of mutations in the kinase domain of PIK3CA (p.H1047R) with late recurrence of locally advanced BC and with non-Slavic ethnic origin of patients were found. Conclusion. PIK3CA mutation rate of 32% confirms high prevalence of mutation in Russian population, with some differences reflecting the ethnic origin of patients.


  • Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer

    by Fedor V. Moiseyenko, Ekaterina S. Kuligina, Albina S. Zhabina, Sergey A. Belukhin, Tatiana A. Laidus, Aleksandr S. Martianov, Kirill A. Zagorodnev, Tatyana N. Sokolova, Svetlana A. Chuinyshena, Maxim M. Kholmatov, et al.

    Purpose This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). Methods Serial plasma samples were collected from 30 patients with EGFR-driven non-small cell lung cancer before intake of the first tablet and at 0.5, 1, 2, 3, 6, 12, 24, 36 and 48 h after the start of the therapy. The content of EGFR alleles (exon 19 deletions or L858R) in ctDNA was measured by ddPCR. Results ctDNA was detected at base-line in 25/30 (83%) subjects. Twelve (50%) out of 24 informative patients showed > 25% reduction of the ctDNA content at 48 h time point; all these patients demonstrated disease control after 4 and 8–12 weeks of therapy. The remaining 12 individuals showed either stable content of EGFR-mutated ctDNA (n = 5) or the elevation of ctDNA concentration (n = 7). 10 of 12 patients with elevated or stable ctDNA level achieved an objective response at 4 weeks, but only 5 of 10 evaluable patients still demonstrated disease control at 8–12 weeks (p = 0.032, when compared to the group with ctDNA decrease). The decline of the amount of circulating EGFR mutant copies at 48 h also correlated with longer progression-free survival (14.7 months vs. 8.5 months, p = 0.013). Conclusion Comparison of concentration of EGFR-mutated ctDNA at base-line and at 48 h after the start of therapy is predictive for the duration of TKI efficacy.


  • Open Access

    175 Cost-efficient analysis of BRCAness status in high-grade serous ovarian carcinomas

    by E Imyanitov, A Sokolenko, T Gorodnova, I Bizin, E Kuligina, K Kotiv, A Romanko, T Ermachenkova, A Ivantsov, E Preobrazhenskaya, et al.

    Introduction/Background*Paclitaxel/carboplatin (TCbP) is a standard therapy for high-grade serous ovarian cancer (HGSOC), however many patients do not benefit from this combination. Methodology Genetic profiling was performed for 71 HGSOC consecutive patients, who received neoadjuvant chemotherapy (NACT). Result(s)*BRCA1/2 germline mutation carriers (n = 22) had longer treatment-free interval (TFI) than non-carriers (n = 49) (9.5 vs. 3.8 months; P = 0.007). 51 HGSOCs with sufficient quality of tumor DNA were examined by the SeqCap EZ CNV/LOH Backbone Design NGS panel, which systematically spans the entire genome at 50 kb intervals. All 13 tumors obtained from BRCA1/2 germline mutation carriers and 12 sporadic HGSOCs had high number of evenly spread chromosomal breaks, that was defined as a BRCAness phenotype; median TFI for this combined group approached 9.5 months. The remaining 26 HGSOCs had similarly high global LOH score (above 20%); however, in contrast to BRCAness tumors, LOH involved large chromosomal segments; these patients had significantly lower TFI (3.7 months; P = 0.006). Comparison between this newly developed BRCAness test, which discriminated tumors simply by the number of affected genomic segments, and the commonly accepted HRD scoring system, revealed high concordance of the results and at least non-inferior clinical performance of our assay. Virtually all tumors with BRCAness (23/25 [92%]) demonstrated gain at MYC locus, while this event was less common in non-BRCAness HGSOCs (12/26 [46%]; P = 0.0006). All patients with CCNE1 amplification (n = 7), TP53 R175H substitution (n = 6), and RB1 mutation (n = 4) had poor response to TCbP. Conclusion*BRCA1/2 germ-line testing has superior performance in identifying responders to TCbP. Simple and rapid PCR-based tests for MYC and CCNE1 amplification allow to classify patients for potential responders and non-responders with a reasonable level of accuracy. BRCAness phenotype can be reliably detected by a laboratory-scale NGS assay, which evaluates the total number of chromosomal breaks. It is of concern that TCbP is being routinely administered both to potential responders and to potential non-responders to this scheme. Novel treatment options for the latter category of HGSOC patients need to be searched within preclinical and clinical studies.

  • Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal

    by Ekaterina S. Kuligina, Roman Meerovich, Kirill A. Zagorodnev, Maxim M. Kholmatov, Tatyana N. Sokolova, Tatiana A. Laidus, Aleksandr A. Romanko, Aleksandr S. Martianov, Maria O. Anisimova, Olga A. Zaitseva, et al.